Anna Pirttikoski

Multi-omic profiling reveals antibody-drug conjugate targetability in ovarian cancer

Abstract Antibody-drug conjugates (ADCs) require high and homogeneous target expression for optimal efficacy, yet the spatial, temporal, and cellular heterogeneity of clinically approved ADC targets in high-grade serous ovarian cancer (HGSC) remains incompletely defined. We analy...